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Abstract
Background: On-pump cardiac surgery triggers a significant postoperative systemic inflammatory response,
sometimes resulting in multiple-organ dysfunction associated with poor clinical outcome. Extracorporeal cytokine
elimination with a novel haemoadsorption (HA) device (CytoSorb®) promises to attenuate inflammatory response.
This study primarily assesses the efficacy of intraoperative HA during cardiopulmonary bypass (CPB) to reduce the
proinflammatory cytokine burden during and after on-pump cardiac surgery, and secondarily, we aim to evaluate
effects on postoperative organ dysfunction and outcomes in patients at high risk.
Methods/design: This will be a single-centre randomised, two-arm, patient-blinded trial of intraoperative HA in
patients undergoing on-pump cardiac surgery. Subjects will be allocated to receive either CPB with intraoperative
HA or standard CPB without HA. The primary outcome is the difference in mean interleukin 6 (IL-6) serum levels
between the two study groups on admission to the intensive care unit. A total number of 40 subjects was calculated
as necessary to detect a clinically relevant 30 % reduction in postoperative IL-6 levels. Secondary objectives evaluate
effects of HA on markers of inflammation up to 48 hours postoperatively, damage to the endothelial glycocalyx and
effects on clinical scores and parameters of postoperative organ dysfunction and outcomes.
Discussion: In this pilot trial we try to assess whether intraoperative HA with CytoSorb® can relevantly reduce
postoperative IL-6 levels in patients undergoing on-pump cardiac surgery. Differences in secondary outcome variables
between the study groups may give rise to further studies and may lead to a better understanding of the mechanisms
of haemoadsorption.
Trial registration: German Clinical Trials Register number DRKS00007928 (Date of registration 3 Aug 2015)
Keywords: Haemoadsorption, Cardiac surgery, Cardiopulmonary bypass, Cytokines, Inflammation, Glycocalyx shedding
Background
Cardiac surgery, particularly on-pump, causes a sys-
temic inflammatory response syndrome (SIRS) with a
marked release of cytokines. Proinflammatory media-
tors, such as IL-6, IL-8, and TNF-alpha reach peak
levels 2 to 4 hours after termination of cardiopulmo-
nary bypass (CPB) and decrease to almost normal
levels within 24 hours [1]. SIRS after cardiac surgery is
associated with postoperative multiorgan system dys-
function and major complications [2, 3]. The proin-
flammatory cytokine burden correlates with poor
postoperative outcome [4]. So far, intraoperative use
of leucocyte filtration, endotoxin adsorption, or ultra-
filtration during CPB in cardiac surgery has not been
able to show consistent results in removal of cytokines
or other inflammatory mediators. Although use of
adsorption and filtration devices was safe and well-
tolerated, studies failed to demonstrate positive effects
on clinical outcome [5–8].
A novel extracorporeal sorbent haemoadsorption (HA)
device (CytoSorb®) was recently developed for cytokine
removal from the blood and is now approved in the
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European Union. It is broadly indicated for any clinical
situation where cytokine levels are elevated. CytoSorb® is
clinically proven to reduce cytokine storm in a multi-
centre, randomised European Sepsis Trial conducted in
Germany. Haemoadsorption was safe and well-tolerated
in more than 300 human treatments in critically ill pa-
tients with sepsis and lung injury [9], and has been safe
in more than 650 human treatments overall. Early data
suggests that HA with CytoSorb® can reduce organ in-
jury and improve survival in patients at high risk, par-
ticularly those with very high cytokine levels and who
are older than age 65. A recent systematic review and
meta-analysis [10] concluded that among current
adsorbing techniques, CytoSorb® may be the most prom-
ising due to data from animal studies [11–13] and first
clinical results [14].
To date there is limited data that HA with CytoSorb®
is able to reduce the effects of the inflammatory re-
sponse after cardiac surgery. However, positive clinical
effects at our institution have led to a broader use of this
novel technique in patients at high risk for postoperative
complications. In this pilot trial we investigate whether
an intraoperative use of HA with CytoSorb® in the CPB
circuit can effectively reduce postoperative levels of
proinflammatory cytokines and may attenuate postoper-
ative systemic inflammatory response.
Methods/design
This will be a single-centre randomised, two-arm,
patient-blinded trial of the effects of intraoperative HA
on postoperative inflammatory response and organ dys-
function in patients undergoing on-pump cardiac sur-
gery. Trial flow per the Consolidated Standards of
Reporting Trials (CONSORT) guidelines [15] is shown
in Fig. 1.
Ethics
The study was approved by the Ethics committee of
the Medical Faculty of the Ruhr University Bochum
(reference number 5094–14) and the study was regis-
tered in the German Clinical Trials Register (registry
number DRKS00007928). The study will be conducted
in accordance with the Helsinki Declaration and the
ICH-GCP guidelines. Written informed consent will
be obtained from all subjects prior to study inclusion
and randomisation.
Fig. 1 Consolidated Standards of Reporting Trials (CONSORT) flow diagram of the REmoval of Cytokines during CArdiac Surgery (RECCAS) trial. A
single-centre randomised, two-arm, controlled, patient-blinded trial of the effects of intraoperative haemoadsorption on postoperative inflammatory
response and organ dysfunction in patients undergoing on-pump cardiac surgery
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Study intervention
Subjects will be randomly allocated to receive either
intraoperative HA during cardiopulmonary bypass
(CPB) or standard CPB without HA. The HA device
will be included in the CPB circuit between the oxy-
genator and the venous reservoir. An additional pump
will ensure a defined blood flow of 400 mL/min
through the HA device (Fig. 2). The study will be con-
ducted at the BG University Hospital Bergmannsheil
(Bochum, Germany).
Recruitment and data collection
Subjects for the study will be enrolled only at predefined
study days. Study days depend on the availability of a
perfusionist trained on the use of CytoSorb®, and a
heart-lung machine (HLM) approved for the inclusion of
the haemoadsorber in the CPB circuit. Furthermore, at
least one member of the study team has to be on service
on the day of surgery as well as on ICU days 1 and 2.
On the day before a predefined study day, the OR plan
will be screened for patients eligible for the study. The
OR plan is made by a team not associated to the study
group. Eligible patients will be asked to consent to
the study. A list of patients screened for inclusion cri-
teria at predefined study days will be generated, and
data on the recruitment process will be published
with the final manuscript.
Clinical data and data on outcome parameters will
be documented in a paper case report form (CRF)
during daily visits by the members of the study team.
Afterwards, all data will be transferred to REDCap™
(Research Electronic Data Capture), a web-based data-
base for research studies. REDCap™ is a secure, web-
based application designed to support data capture for
research studies, providing 1) an intuitive interface for
validated data entry; 2) audit trails for tracking data
manipulation and export procedures; 3) automated
export procedures for seamless data downloads to
common statistical packages; and 4) procedures for
importing data from external sources [16]. Paper CRFs
and the electronic database will be stored for at least
10 years according to the ICH-GCP guidelines.
Randomisation and blinding
Assignment to the two treatment arms will be per-
formed on a 1:1 basis using a computer-generated sys-
tem after induction of anaesthesia before the beginning
of surgery. Patients will be kept blinded. The lab analyst
will also be blinded to patients’ data and to the different
study groups. Thus, laboratory outcome parameters are
analysed independently from the clinical data.
The haemoadsorption device (CytoSorb®)
The CytoSorb® adsorber is composed of biocompatible
porous polymer beads able to remove substances from
whole blood based on pore capture and surface adsorp-
tion. Substances that are larger than the pores, such as
blood cells, cannot get into the pores and go around the
Fig. 2 Integration of the haemoadsorption device into the cardiopulmonary bypass (CPB) circuit. Oxygenated blood is taken from the
oxygenator of the heart-lung machine (HLM), and an additional blood pump ensures a defined blood flow of 400 mL/min through the
adsorber to the venous reservoir of the HLM
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beads. Very small substances, such as electrolytes and
other blood chemistry components, are also not cap-
tured. Appropriately sized molecules in the 5–60 kDa
range, however, become trapped in the vast network of
pores and channels in every bead, and are permanently
eliminated from the blood. CytoSorb® was specifically
designed to target this molecular weight range, given
that the majority of cytokines and inflammatory media-
tors fall within this size spectrum. The technology is not
an affinity-based sorbent and does not use antibodies,
ligands, cells or drugs [17].
Table 1 shows technical data of the CytoSorb® adsorber
according to the manufacturer information [17]. Cyto-
Sorb® is CE Mark approved under the Medical Devices
Directive, is ISO 10993 biocompatible, and is manufac-
tured in the United States under ISO 13485 certification.
Over 5,500 treatments have been performed in more
than 200 centres around the world. The device is consid-
ered safe and well-tolerated. CytoSorb® has standard
dialysis connectors that allow integration with haemodi-
alysis machines and heart-lung machines found in most
hospitals today. It is compatible with either systemic
heparin or regional citrate anti-coagulation, with the
same anti-coagulation requirements as for dialysis or
on-pump cardiac surgery [17]. Based on the Company’s
European Sepsis Trial [9], there is no adverse removal of
leukocytes or red blood cell haemolysis during treat-
ment. As with most extracorporeal therapies, some
platelets are removed during therapy, but the amount
was less than 10 % per treatment and was not clinically
significant. Average albumin removal was less than 10 %
after seven days of CytoSorb® therapy and not clinically
significant [9].
Inclusion criteria
 Adult patients > 65 years undergoing cardiac surgery
with an expected CPB duration >90 minutes
 Written informed consent
Exclusion criteria
 Age < 65 years
 Missing informed consent
 Planned CPB temperature < 32 °C
 Emergency surgery
 Acute infective endocarditis
 AIDS with a CD4 count of < 200/μL
 Previous renal replacement therapy
 Pre-existing kidney disease not requiring RRT
(GFR < 30 mL/min)
 Prior kidney transplant
 Application of contrast medium on the day of
surgery
 Immunosuppressive therapy or long-term therapy
with corticosteroids
 Participation in another clinical intervention trial
Standardisation of anaesthesia, CPB management and ICU
treatment
All patients will receive standard anaesthetic treatment.
Intraoperative transoesophageal echocardiography is
performed for optimisation of haemodynamic manage-
ment if indicated.
Standard of care treatment in the ICU is given to all
study subjects. Especially for mechanical ventilation, nu-
trition, sedation, anticoagulation, and blood glucose con-
trol, therapy is based on local treatment protocols.
In the ICU, treatment with vasopressors, inotropes,
and fluids is guided by haemodynamic monitoring using
a transpulmonary thermodilution technique (PiCCO®)
and derived dynamic parameters. Echocardiography
(transthoracic or transoesophageal) is performed daily in
ICU patients and whenever indicated. Optimisation of
haemodynamics and preload guided by PiCCO® and/or
echocardiography is mandatory before starting renal re-
placement therapy (RRT).
RRT will be started in the presence of absolute indica-
tions. Absolute indications according to KDIGO (Kidney
Disease: Improving Global Outcomes) guidelines are
when life-threatening refractory changes in fluid, electro-
lyte, and acid–base balance (for example, hyperkalaemia,
acidaemia, pulmonary oedema, uraemic complications)
exist [18]. RRT will also be initiated in patients with
acute kidney injury (AKI) with urine output <0.3 mL/kg/
h for ≥24 hours or anuria for ≥12 hours (AKIN 3). In
patients with AKIN 2, RRT should be started when
concomitant ongoing organ failure (development or
progression of non-renal Sequential Organ Failure
Assessment [SOFA] organ system subscore ≥2) and/or
haemodynamic instability (norepinephrine/epineph-
rine ≥0.1 μg/kg/min or use of terlipressin) are present.
Continuous veno-venous haemodialysis (CVVHD)





Blood flow rates min-max 100–400 mL/min
Max. treatment duration 24 hours
Anticoagulation Possible with heparin or citrate
Sterilisation Gamma sterilisation
Further details Latex- and polyhexahydrotriazines-free
product
Storage conditions 1 to 40 °C; upright storage
Modified from [16]
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(30 mL/kg/h) with regional citrate-anticoagulation is
used in all ICU patients with AKI. RRT will be discon-
tinued if renal recovery defined by urine output
(>400 mL/24 h) and creatinine clearance (>20 mL/
min) occurs [19].
Primary objective
Table 2 shows an overview on the time points of routine
blood samples and outcome laboratory parameters dur-
ing the study period. The study aims to assess the effi-
cacy of intra-operative haemoadsorption with CytoSorb®
to remove cytokines from circulation for prevention of
surgical associated inflammatory response and complica-
tions in patients at high risk.
 The primary outcome is the difference in mean IL-6
serum levels between the two study groups on ad-
mission to the ICU.
Secondary objectives
 Length of hospital stay
 Length of ICU stay
 ICU mortality
 Hospital mortality
 Surveillance of vital parameters in the ICU
(haemodynamic and ventilation parameters and
data for support of other organs in the ICU will
be monitored due to the standard of care)
 Daily SOFA organ failure scores in the ICU and on
hospital discharge
 Incidence of postoperative delirium (NuDESC
scores)
 Infections
 Incidence of acute kidney injury (AKI) of any stage
according to the AKIN classification [18]
 Duration of renal support
 Renal function on hospital discharge
 Serum markers of glycocalyx shedding (syndecan-1,
heparan-sulphate and hyaluronan)
 Blood kinetics of free haemoglobin, myoglobin and
haptoglobin
 Hepatic function (liver enzymes, indocyanine green
[ICG] plasma disappearance rate [PDR])
 Markers of mast cell degranulation (for example,
mast cell tryptase)
 Blood and urine cytokine kinetics
Cytokine levels (such as IL-10 and TNF-alpha) and
other routinely used biomarkers (such as CRP and
PCT) will be assessed daily from before start of CPB
up to 48 hours after ICU admission. In the HA group,
additionally blood samples for primary and secondary
laboratory outcome parameters are taken from the














Routine blood samples X X X X X X X
IL-6 X X X X X X X
IL-2 X X X X X X X
IL-8 X X X X X X X
IL-10 X X X X X X X
TNF-alpha X X X X X X X
C3a X X X X X X X
Free haemoglobin X X X X X X X
Haptoglobin X X X X X X X
Myoglobin X X X X X X X
Fibrinogen X X X X X X X
Syndecan-1 X X X X X X X
Hyaluronan X X X X X X X
Heparan sulphate X X X X X X X
Markers of mast cell
degranulation
X X X X X X X
aIntraoperative cytokine kinetics and markers of secondary objectives will only be assessed in patients allocated to the haemoadsorption device at 10, 30 and
60 min after initiation of cardiopulmonary bypass (CPB). For this, blood samples at the defined time points will be taken from the CPB circuit both before and
after use of the haemoadsorption device
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CPB circuit before entering and after the passage of
the HA device at 10, 30 and 60 minutes after CPB
start (Table 2).






 Clinical scores (ASA, Euroscore, Thakar score,
NuDESC)
Anaesthesia and surgery:
 Duration of operation, CPB and aortic cross-
clamping
 Vasopressors and inotropics
 Fluids and fluid balance
 Transfusion and coagulation factors
 Urine output
 Baseline IL-6 concentrations (after induction of an-
aesthesia) in all patients. Intraoperative IL-6 kinetics
in patients with haemoadsorption.
 Baseline concentration of secondary laboratory
outcomes (after induction of anaesthesia) in all
participants. Secondary laboratory outcomes (for
example, cytokines, free haemoglobin, myoglobin) at
10, 30 and 60 minutes after CPB start, only in
patients with haemoadsorption.
ICU:
 Daily SOFA scores




 Infectious complications, antibiotics
 Fluid balance
 Renal function, renal replacement therapy
 Cytokine concentrations (including IL-6) up to day
2 in the ICU
 Secondary laboratory outcomes up to day 2 in
the ICU
Follow-up (at hospital discharge):
 Length of stay in the ICU
 Length of stay in the hospital
 Renal function on ICU/hospital discharge
 Readmission to ICU
 Cause of death
Sample size calculation and statistical analysis
Based on previous research we expect a mean IL-6 con-
centration of 200 (SD 50) pg/mL in the control group
[7, 20–22] and a reduction of 30 % (that is, 140 (SD 35)
pg/mL) by intraoperative haemoadsorption with Cyto-
Sorb®. The Welch-modified t-test requires 15 patients
per group to reach a power of 95 % at two-sided signifi-
cance level 5 % (calculated with Stata 14.1; StataCorp,
College Station, TX, USA; command “power two means
200 140, sd1(50) sd2(35) power(0.95)”). To compensate
for non-evaluable patients and, possibly, the use of non-
parametric methods, 20 patients per group will be in-
cluded and randomised.
The full analysis set is derived from the intention-to-
treat principle, meaning that all patients randomised and
operated on will be analysed as assigned—apart from
non-evaluable patients, that is, those without a valid IL-
6 serum level measurement on ICU admission. The
Welch-modified t-test (with corresponding 95 % confi-
dence) interval will be applied to test the null hypothesis
of equal mean IL-6 serum levels in treatment groups on
ICU admission. In the case of relevantly skewed (non-
normal) data distributions within groups, the non-
parametric Wilcoxon rank sum test (with corresponding
95 % confidence interval) will be applied.
Secondary outcome measures in the two treatment
groups (all available observations) will be summarised
descriptively either by count and percentage or by
mean, standard deviation and percentiles (0, 25, 50, 75,
100), contingent on distributional characteristics. Ad-
verse event data will be listed and aggregated by cat-
egory. Significance tests and confidence intervals will
be calculated to support interpretation. A subgroup
analysis will be performed by sex (assumed inclusion
ratio 1.5 (male): 1.0 (female)). Statistical calculations
will be done with SPSS Statistics software (IBM Corp.,
Armonk, NY, USA).
Discussion
In this pilot trial we will assess if intraoperative hae-
moadsorption with CytoSorb® can significantly reduce
postoperative IL-6 serum levels in patients undergoing
on-pump cardiac surgery. The adsorber has been suc-
cessfully used in different clinical settings, and the
number of published case reports is steadily increasing
[23–26]. However, little is known about the effects of
HA with CytoSorb® during on-pump cardiac surgery.
Thus, the present study was designed to learn about
the effects of HA on intra- and postoperative patterns
of systemic inflammation and of organ dysfunction.
We chose the difference of serum IL-6 levels on ICU
admission as the primary outcome, as IL-6 is a typical
proinflammatorily acting cytokine. IL-6 levels rise sig-
nificantly after cardiac surgery and peak 2 to 4 hours
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after termination of CPB. Elevated levels of IL-6 are
associated with postoperative myocardial ischaemia,
development of low cardiac output, and requirement
for vasopressors [27, 28]. High levels of IL-6 on ICU
admission after cardiac surgery also correlate well
with the development of postoperative infections [22].
Thus, reducing IL-6 from the CPB circuit may at-
tenuate the postoperative inflammatory response. For
our study we defined a 30 % reduction of IL-6 to be
clinically relevant. However, our study also focuses on
other mediators of inflammation as secondary out-
comes. Increased levels of IL-8 are associated with
length of postoperative inotropic support and dur-
ation of mechanical ventilation, and TNF-alpha levels
correlated with impaired left ventricular contractility
[1]. Furthermore, kinetics of IL-10, a typical represen-
tative of an anti-inflammatory cytokine, will also be
evaluated. IL-10 modulates the compensatory anti-
inflammatory response syndrome (CARS) counteract-
ing SIRS [29–31]. An overwhelming anti-inflammatory
response can lead to immunosuppression and suscep-
tibility to postoperative infections.
Our study also aims to evaluate other mechanisms
of postoperative organ failure. Increased levels of free
haemoglobin and myoglobin contribute to the patho-
genesis of cardiac surgery-associated AKI (CSA-AKI)
[32]. As CytoSorb® effectively removes cytokines with
a molecular weight of approximately 10–50 kDa, one
can assume that both free haemoglobin and myoglobin
are removed from the CPB as well. This may have a
further protective effect on the kidney and probably
contributes to preservation of renal function after car-
diac surgery.
Another consequence of hypoxia, ischaemia and reper-
fusion is damage of the endothelial glycocalyx [33, 34],
probably by a purine mediated mast cell-dependent
mechanism [35, 36]. In turn, degradation products (such
as syndecan-1, hyaluronan and heparan-sulphate) may
increase inflammatory response through toll-like recep-
tor 4 (TLR-4)-mediated positive feedback mechanism.
Thus, in this study we also try to assess whether
circulating glycocalyx degradation products are elimi-
nated by intraoperative haemoadsorption, and if in-
flammatory response is accompanied by decreased
glycocalyx shedding.
In the haemoadsorption group, we additionally evalu-
ate the ability of CytoSorb® to significantly adsorb differ-
ent cytokines and other mediators of interest during
CPB. For this, blood samples for primary and secondary
laboratory outcome parameters are taken before entering
and after the passage of the HA device at 10, 30 and
60 minutes after CPB start.
Finally our pilot study provides a link between insights
into inflammatory response after intraoperative HA and
clinical outcomes. Possible differences in clinical outcome
parameters, such as mortality, length of stay, numbers of
complications, infections and SOFA scores between the
study groups may give rise to further studies and possibly
lead to a better understanding of mechanisms of hae-
moadsorption. As this is a clinical study, one limitation
could be that group differences in CBP duration may in-
fluence peak levels of cytokines. Furthermore, the interval
between end of CPB and ICU admission is not equal in all
patients. But from our clinical experience we know that
those differences are negligible, and we assume that effects
on cytokine levels are not of relevance.
Trial status
This randomised pilot trial was designed as an
investigator-initiated study for which BG University
Hospital Bergmannsheil (Bochum, Germany) was as-
sumed to be acting as sponsor The first participant
was included on 26 January 2015. To date, 17 partic-
ipants have been recruited.
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